Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

Initiative Lowers Unnecessary Aspirin Use in Warfarin Users

News Daily News

Initiative Lowers Unnecessary Aspirin Use in Warfarin Users

September 26, 2022

FDA Approves Two Additional Indications for Rivaroxaban in Children

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

December 21, 2021

Long-term Anticoagulation After Unprovoked VTE: New Insights

News Daily News

Long-term Anticoagulation After Unprovoked VTE: New Insights

September 13, 2021

FDA Approves Dabigatran for VTE in Children

News Daily News

FDA Approves Dabigatran for VTE in Children

June 22, 2021

ACC Issues New Guidance Around Antithrombotic Choices in A-fib, VTE

News Daily News

ACC Issues New Guidance Around Antithrombotic Choices in A-fib, VTE

December 22, 2020

In COVID-19 Pulmonary Embolism, Nontraditional Risk Factors Dominate

News Daily News

In COVID-19 Pulmonary Embolism, Nontraditional Risk Factors Dominate

Yael L. Maxwell

July 21, 2020

ESC Updates Guidance on Management of Acute Pulmonary Embolism

News Conference News ESC 2019

ESC Updates Guidance on Management of Acute Pulmonary Embolism

September 06, 2019

Disparities Seen in Uptake of DOACs for VTE

News Daily News

Disparities Seen in Uptake of DOACs for VTE

April 05, 2019

NOACs Significantly Curb Risk of VTE in Cancer Patients

News Daily News

NOACs Significantly Curb Risk of VTE in Cancer Patients

December 06, 2018

News Daily News

Apixaban Noninferior to Standard Therapy for Acute Venous Thromboembolism

July 05, 2013

News Daily News

El Apixaban No es Inferior a la Terapia Estándar en el Tratamiento de los Tromboembolismos Venosos Agudos

July 05, 2013

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.